{"SPADE_N_06003": {"Clinical Information": [], "Patent Information": [{"Patent No": "US 8202835 B2", "Patent Link": "http://www.lens.org/lens/patent/US_8202835_B2", "Patent Type": "Granted Patent", "Publication Date": "2012-6-19", "Family Info": "US8426366,US20090048167,US20120277157", "Patent Title": "Disease treatment via antimicrobial peptides or their inhibitors.", "Abstract": "The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease."}, {"Patent No": "US 7071293 B1", "Patent Link": "http://www.lens.org/lens/patent/US_7071293_B1", "Patent Type": "Granted Patent", "Publication Date": "2006-7-4", "Family Info": "US5618675,US20050277176A1,EP1359930A2,WO9402589", "Patent Title": "Alpha Helical Peptides With Broad Spectrum Antimicrobial Activity That Are Insensitive To Salt", "Abstract": "The present invention relates to the use of antimicrobial peptides in the inhibition of microbial growth and proliferation. Novel antimicrobial truncated peptides are disclosed which are based upon SMAP 29 and RCAP 24, but which contain a lesser number ofmino acid residues yet still retain bactericidal activity. In addition, synthetic peptides based upon the SMAP 29 protein are disclosed which have fewer amino acid residues and include substitutions yet retain substantial activity. The invention also relates to a method of inhibiting microbial growth by administering an effective amount of a peptide in accordance with the invention, or by combining the peptides with other antimicrobial agents or antibiotics."}], "Sequence Information": {"SPADE ID": "SPADE_N_06003", "Peptide Name": "CAP18", "Source": "Oryctolagus cuniculus", "Family": "Not found", "Gene": "camp", "Sequence": "GLRKRLRKFRNKIKEKLKKIGQKIQGLLPKLAPRTDY", "Sequence Length": 37, "UniProt Entry": ["http://www.uniprot.org/uniprot/G1T9L4"], "Protein Existence": "Homology", "Biological Activity": ["Antimicrobial", "Antibacterial", "Anti-Gram+", "Anti-Gram-"], "Target Organism": "[Ref.11557478]Gram-negative bacteria:Pseudomonas aeruginosa(MIC=1-32 µg/ml); Pseudomonas aeruginosa(MIC50=4 µg/ml); Pseudomonas aeruginosa(MIC90=16 µg/ml); Stenotrophomonas maltophilia(MIC=2-16 µg/ml); Achromobacter xylosoxidans(MIC=2-32 µg/ml).[Ref.10768969]Gram-positive bacteria:Staphylococcus aureus ATCC 33591(MIC=1.24 µM ); Staphylococcus aureus ATCC 33591(100 mM NaCl,MIC=1.36 µM); Staphylococcus aureus 930918-3(MIC=0.41 µM); Staphylococcus aureus 930918-3(100 mM NaCl,MIC=0.63 µM);Gram-negative bacteria:Pseudomonas aeruginosa PAO1(25 mM NaCl,EC50=0.22±0.05 µM); Pseudomonas aeruginosa PAO1(175 mM NaCl, EC50=0.11±0.02 µM); Escherichia coli DH5α(MIC=0.19 µM); Escherichia coli DH5α(100 mM NaCl, MIC=0.21 µM); Escherichia coli ML-35p(MIC=0.05 µM); Escherichia coli ML-35p(100 mM NaCl, MIC=0.09 µM); Pseudomonas aeruginosa PAO1(MIC=0.20 µM); Pseudomonas aeruginosa PAO1(100 mM NaCl, MIC=0.62 µM); Pseudomonas aeruginosa MR3007(MIC=0.05 µM); Pseudomonas aeruginosa MR3007(100 mM NaCl, MIC=0.36 µM).[Ref.26656394]Gram-negative bacteria:Yersinia ruckeri 392/2003(MIC=2-4 µg/ml); Aeromonas salmonicida ATCC 49385(MIC=2 µg/ml); Salmonella enterica serovar Typhimurium LT2(MIC=4-8 µg/ml); Campylobacter jejuni NCTC 11168(MIC=1 µg/ml); Escherichia coli ATCC 25922(MIC=4-8 µg/ml ); Pseudomonas aeruginosa ATCC 27853(MIC=4-8 µg/ml); Escherichia coli BW25113(MIC=4-8 µg/ml); Escherichia coli BW25113 del-rfaC(MIC=4 µg/ml); Escherichia coli ATCC 25922 del-rfaC(MIC=2 µg/ml);Gram-positive bacterial:Flavobacterium psychrophilum 1947(MIC>>256 µg/ml); Staphylococcus aureus ATCC 29213(MIC>=32 µg/ml); Enterococcus faecalis ATCC 29212(MIC=8 µg/ml); Listeria monocytogenes N22-2(MIC=2-4 µg/ml).[Ref.30245684]Gram-negative bacterial:Escherichia coli ATCC 25922 del-waaC(MIC=2-4 µg/ml); Escherichia coli ATCC 25922 del-waaE(MIC=4 µg/ml); Escherichia coli ATCC 25922 del-waaF(MIC=2-4 µg/ml); Escherichia coli ATCC 25922 del-waaG(MIC=4 µg/ml); Escherichia coli JW3596(MIC=4 µg/ml); Escherichia coli JW1667(MIC=2-4 µg/ml ).[Ref.29852015]Gram-negative bacterial:Aeromonas salmonicida ATCC 33658(MIC=4 µg/ml);Gram-positive bacterial:Lactococcus lactis IL1403(MIC=1-2 µg/ml).", "Hemolytic Activity": "[Ref.10768969]non-hemolysis against Human erythrocytes up to 500 µg/ml.[Ref.26656394]1% hemolysis against Horse erythrocytes at 64 µg/ml.", "Cytotoxicity": "Not found", "Binding Target": "liposomes", "Linear/Cyclic": "Linear", "N-terminal Modification": "Free", "C-terminal Modification": "Free", "Stereochemistry": "L", "Structure Description": "The peptide adopted an appreciable α-helical content in the presence of the organic cosolvent 40% trifluoroethanol and in the presence of 0.1% lipopolysaccharide.", "Formula": "C202H356N64O47", "Mass": 4433.39, "PI": 11.54, "Net Charge": 12, "Hydrophobicity": -1.1, "Half Life": "Mammalian:30 hourYeast:>20 hourE.coli:>10 hour", "Function": "Antibacterial activity against Gram-positive bacteria and Gram-negative bacteria.CAP18 were active against P. aeruginosa, E. coli, S. aureus, and MRSA.", "Literature": [{"Title": "Cathelicidin peptides inhibit multiply antibiotic-resistant pathogens from patients with cystic fibrosis.", "Pubmed ID": "11557478", "Reference": "Antimicrob Agents Chemother. 2001 Oct;45(10)2838-2844.", "Author": "Saiman L, Tabibi S, Starner TD, San Gabriel P, Winokur PL, Jia HP, McCray PB Jr, Tack BF.", "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=11557478"}, {"Title": "Bactericidal activity of mammalian cathelicidin-derived peptides.", "Pubmed ID": "10768969", "Reference": "Infect Immun. 2000 May;68(5)2748-2755.", "Author": "Travis SM, Anderson NN, Forsyth WR, Espiritu C, Conway BD, Greenberg EP, McCray PB Jr, Lehrer RI, Welsh MJ, Tack BF.", "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=10768969"}, {"Title": "Comparative Evaluation of the Antimicrobial Activity of Different Antimicrobial Peptides against a Range of Pathogenic Bacteria.", "Pubmed ID": "26656394", "Reference": "PLoS One. 2015 Dec 11;10(12)e0144611.", "Author": "Ebbensgaard A, Mordhorst H, Overgaard MT, Nielsen CG, Aarestrup FM, Hansen EB.", "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=26656394"}, {"Title": "The Role of Outer Membrane Proteins and Lipopolysaccharides for the Sensitivity of Escherichia coli to Antimicrobial Peptides.", "Pubmed ID": "30245684", "Reference": "Front Microbiol. 2018 Sep 7;92153.", "Author": "Ebbensgaard A, Mordhorst H, Aarestrup FM, Hansen EB.", "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=30245684"}, {"Title": "Dissection of the antimicrobial and hemolytic activity of Cap18 Generation of Cap18 derivatives with enhanced specificity.", "Pubmed ID": "29852015", "Reference": "PLoS One. 2018 May 31;13(5)e0197742.", "Author": "Ebbensgaard A, Mordhorst H, Overgaard MT, Aarestrup FM, Hansen EB.", "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=29852015"}], "Frequent Amino Acids": "KLR", "Absent Amino Acids": "CHMOSUVW", "Basic Residues": 14, "Acidic Residues": 2, "Hydrophobic Residues": 14, "Polar Residues": 20, "Positive Residues": 14, "Negative Residues": 2, "Similar Sequences": [{"SPADE_ID": "SPADE_N_03505", "Similarity": 1.0, "Sequence": "GLRKRLRKFRNKIKEKLKKI"}, {"SPADE_ID": "SPADE_N_12833", "Similarity": 1.0, "Sequence": "GGGGLRKRLRKFRNKIKEKLKKIGQKIQGLLPKLA"}, {"SPADE_ID": "SPADE_UN_08128", "Similarity": 1.0, "Sequence": "GLRKRLRKFRNKIKEKLKKIG"}]}}}